• Kane Biotech Q1 2026 revenue fell 89.52% to $43,218; net loss narrowed to $(714,827) from $(1,218,497) a year earlier.
• Gross loss was $(3,899), swinging from a $42,447 gross profit in Q1 2025; operating expenses dropped 44.38% to $669,402.
• Cash totaled $395,058 at March 31, 2026; an oversubscribed May private placement raised $1.16 million.
• Expanded U.S. commercialization via multiple non-exclusive distribution and sales agent deals; shipments under new partnerships began ramping in Q2 2026.
• Won FDA 510(k) clearance for the revyve Antimicrobial Skin and Wound Cleanser; Interim CEO Robert Huizinga said focus is converting momentum into accelerating revenues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281705PRIMZONEFULLFEED9728423) on May 28, 2026, and is solely responsible for the information contained therein.